Product Images Yervoy

YERVOY* (ipilimumab) injection.*

This appears to be a table or graph with some numerical data and labels. It is not very clear what the numbers and labels represent without additional context. Therefore, a useful description cannot be provided.*

This appears to be a table with data related to the usage of different treatments for cancer (Nivolumab, Ipilimumab (YERVOY), and a combination of both). The table appears to show the number of subjects and their corresponding survival rates in months.*

The text provides a chart regarding the Overall Survival probability for the drugs OPDIVO + ipilmumab and Sunitinib. The chart shows the number of subjects at risk over time in months. The probability of overall survival is not mentioned.*

This is a graph that shows the Probability of Overall Survival in patients treated with a combination of YERVOY + nivolumab and platinum-doublet chemotherapy. The X-axis shows the time in months and the Y-axis shows the Probability of Overall Survival. The blue line represents the YERVOY + nivolumab treatment, and the orange line represents the platinum-doublet chemotherapy treatment. The graph provides a visual representation of the number of subjects at risk, as well as the number of subjects who survived at each point in time.*

This appears to be a graph of Overall Survival for YERVOY + nivolumab vs. Chemotherapy, with survival rate plotted against the number of months.*

This is a description of a graph showing the Overall Survival (in months) of subjects treated either with Yervoy and nivolumab, or with Chemotherapy. The X-axis represents the time of the treatment (in months), and the Y-axis represents the number of subjects at risk. The number of subjects at risk decreases over time and is shown for the different time points on the graph.*

This appears to be a report presenting data on the probability of overall survival for patients receiving a combination of YERVOY, nivolumab, and platinum-doublet chemotherapy compared to those receiving platinum-doublet chemotherapy alone. The report includes a chart showing the number of subjects at risk over time and a graph depicting overall survival in months. Additionally, the report lists survival percentages at specific time intervals for each treatment group.*

This appears to be a table or graph related to the proportion of subjects alive in some study, along with the number of subjects at risk each month. Unfortunately, the text is not easily readable in its current format.*

This may be a graphical representation of Progression Free Survival (PFS) of two treatments: YERVOY + nivolumab and chemotherapy. The PFS is indicated on the y-axis and the time periods on the x-axis. The number of subjects at risk is also provided for each time period. The YERVOY + nivolumab treatment may have shown better PFS than chemotherapy, as indicated by the higher number of subjects at risk in the early time periods. However, without more context or analysis, it is difficult to make definitive conclusions.*

This is a chart that provides information on the probability of progression-free survival per BICR for a treatment called YERVOY + nivolumab compared to chemotherapy. The chart shows the progression-free survival per BICR (in months) and the number of subjects at risk for each treatment group at different time points. There are no other details available.*